Clearside Completes Enrollment in First Phase III Trial of CLS-TA in RVO

June 29, 2018: By Jon Swedien

Clearside Biomedical has completed enrollment in its first Phase III clinical trial studying suprachoroidal CLS-TA used with aflibercept for retinal vein occlusion (RVO), the Alpharetta, Georgia, company announced June 13.

SAPPHIRE is a multicentered, multi-country, randomized, masked, controlled study of 460 patients who are naïve to pharmacologic treatment for RVO.

It will assess whether using suprachoroidal CLS-TA in combination with Eylea offers an opportunity for earlier improved visual outcomes for RVO patients compared with Eylea monotherapy.

The study is also designed to evaluate required treatment frequency for the combination arm compared with the Eylea control arm over the course of the trial.

The company expects to report topline data from the week eight primary endpoint in Q4-2018.

CLS-TA is Clearside’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space.

It has been observed to reduce inflammation and other complications that lead to swelling of the macula, a leading cause of visual impairment and blindness, Clearside said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales